INTRODUCTION:

Microspheres are defined as solid, roughly spherical particles with a diameter ranging from 1 to 1000μm. They can also take the form of microcrystalline particles or be disseminated medications in certain solutions¹. Microspheres and microcapsules are frequently used interchangeably. Microparticles is another term for microspheres. Glass, polymers, and ceramic microspheres are just a few of the materials that may be used to create microspheres. They have a variety of uses, depending on the material and particle size that are employed in building. There are two sorts of microspheres: micrometrics and microcapsules². Micro-capsules are defined as those in which the material that is encapsulated is clearly enclosed by a distinct capsule wall. Additionally, there are micrometrics, which distribute the entrapped material throughout the matrix (see figure 1). The microsphere is crucial in enhancing the absorption of traditional medications and reducing their adverse effects³. The drug must be delivered to the target tissue in the ideal amount and at the ideal timing to produce the least degree of toxicity and side effects in order to achieve maximal therapeutic efficacy. There are several ways to deliver a therapeutic material to the intended location in a manner that allows for regulated, continuous release. One such method is the delivery of medications using microspheres⁴. One of the most fascinating areas of pharmaceutical science research is the creation of novel drug delivery systems with controlled release capabilities. A well-thought-out controlled drug delivery system can improve a particular medicine's therapeutic efficacy and solve some of the issues with traditional therapy. In order to achieve maximal therapeutic efficacy, the drug must be delivered to the target tissue in the ideal amount during the ideal time frame, resulting in low toxicity and negligible side effects⁵. A medicinal ingredient can be delivered to the target place in a number of ways using prolonged controlled release techniques. Accurate targeting and precise delivery of a specific place can be accomplished by the attachment of bioactive molecules to liposomes, bio erodible polymers, implants, monoclonal antibodies, and other powders. Using microspheres as medication carriers is one such strategy^6,7.

Fig. 1: Microsphere

Benefits of microsphere in drug delivery system:

Applications for regulated drug delivery using microspheres include hormone treatment, chemotherapy, cardiovascular illness, therapeutic protein delivery, and vaccine research. When compared to other delivery methods, the use of biodegradable microspheres for medication administration offers many advantages. Instead of requiring multiple doses and guaranteeing sustained and controlled drug delivery over weeks or months, biodegradable polymer offers a way to provide sustained release over a longer period of time^8,9,10. In conventional systems, the drug is typically released shortly after delivery and ceases to function after a brief period of time. Although the likelihood of toxicity issues is reduced when biodegradable polymers are used, there are still by products that must be accepted without causing negative effects¹¹.

Applications of microspheres:

Localized delivery of drug: Drug delivery that is localised allows the substance to be applied specifically to the location where it is needed or desired, hence reducing systemic exposure to the medication¹². This becomes crucial, particularly for hazardous medications that have a history of systemic adverse effects (like chemotherapy treatments).

Continuous medication delivery: The need for repeated injections is decreased when the medication is released in the form of encapsulation over prolonged periods of time¹³. This feature can help patients comply with their medication regimens, particularly when it comes to long-term conditions that call for repeated injections (such a protein deficit).

Drug stabilisation: By shielding the medication from the physiological milieu, the polymer can increase the drug's stability in vivo¹⁴. This specific property makes the method appealing for the administration of medications that are labile, such proteins.

Materials used in the microsphere formulation:

Microspheres used usually are polymers.

They are classified into two types.

1. Synthetic Polymers

2. Natural polymers

Types of microspheres:

1. Bio-adhesive Microspheres:

Microspheres with bio adhesion Adhesion is defined as the process of adhering to a membrane through the utilisation of the water-soluble polymer's sticking abilities. The bio adhesion feature of some polymers, which stick to one another when hydrated, is used by the bio-adhesive drug delivery system to deliver medication to a particular part of the body over an extended period of time^15,16. Thus, by reducing the frequency of dose, the drug's absorption and, consequently, bioavailability are enhanced, leading to increased patient compliance

2. Magnetic Microspheres:

Magnetic microspheres are molecular particles that are so small that they can pass through capillaries without obstructing the oesophagus (less than 4 μm). However, because they are ferromagnetic, they are highly susceptible to being trapped in micro-vessels and drawn through adjacent tissues by a magnetic field of 0.5–0.8 tesla. It is crucial to use magnetic microspheres to guide the treatment to the exact location of the illness^17,18.

· Therapeutic magnetic microspheres

· Diagnostic microspheres

Fig. 2: Magnetic Microsphere

3. Floating Microspheres:

Floating microspheres based on non-effervescent design are the basis of gastroprotective medication delivery techniques. Hollow microspheres, micro balloons, or floating microparticles are terms that are interchangeably used to refer to floating microspheres^19,20. To put it simply, floating microspheres are tiny, hollow particles that lack a centre. These are free-flowing cells with scales ranging from 1 to 1000 μm. (Fig.3)

Fig. 3: Floating Microspheres

4. Radioactive microspheres:

The radioactively interacting microsphere subgroup is often handled similarly to nonradioactive microspheres. Additionally, to the matrix material that characterises the microsphere and confers its targeting capabilities in a certain tissue or organ, the radioactive microsphere invariably contains one, if not more, radionuclides^21,22. Radioactive microspheres can provide high radiation doses to a particular area in small quantities without harming the surrounding natural tissue. (Fig.4)

Fig. 4: Radioactive microspheres

Method of Preparation:

1. Spray Drying:

Using the Spray Drying process, the medication is first disseminated in the polymer solution using high-speed homogenization after the whole polymer has been dissolved in an appropriate volatile organic solvent, such as acetone or dichloromethane. A hot air stream is then used to atomize this dispersion^23,24. The process of atomization results in the production of tiny droplets or fine mists, from which the solvent instantly evaporates to create microspheres with a size range of 1-100μm. The heated air is separated from the microparticles. By using a cyclone separator, then vacuum drying is used to eliminate any solvent residue. Among the principal One of this process's benefits is its ability to function under aseptic environments²⁵. (Fig.5)

Fig. 5: Spray Drying

2. Solvent Evaporation:

This process, known as emulsification, or o/w type emulsion, is carried out in vehicles and involves two phases: an aqueous phase and an organic phase. After this, the solvent evaporates, leaving behind raw nanospheres of microspheres^26,27. (Fig.6)

Fig. 6: Solvent Evaporation

3. Single emulsion technique:

This method, known as sonification, involves dispersing an aqueous polymer solution in an organic phase (oil or chloroform) while continuously stirring. Following this, there are two methods for creating microspheres: first, heat denaturation and chemical crosslinking; next, centrifuging the result and either washing or separating^28,29.

Fig. 7: Single emulsion technique

4. Double emulsion technique:

This approach produces the initial emulsion after adding aqueous solutions of the polymer and medicament to the organic phase. PVA solution and create several emulsions for washing, drying, and solution separation to create microspheres^30,31 (Fig.8).

Fig. 8: Double emulsion technique

5. Phase separation coacervation technique:

This method involves dissolving a medication in an aqueous or organic solution in a polymer solution to create polymer-rich globules or droplets, hardening in an aqueous or organic phase, separating the microspheres, washing them, and finally drying them to a pure state^32,33.

6. Spray drying and spray congealing:

The polymer was dissolved in a suitable volatile organic solvent, such acetone, chloroform, etc., and then homogenised at a high-speed while being atomized in a hot air stream. This caused the polymer to form tiny droplets, which later solidified and formed minute particles ^34,35. (Fig.9)

Fig. 9: Spray drying and spray congealing technique

7. Solvent extraction:

The medication and polymer used in the solvent extraction process need to dissolve in an organic solvent to generate an aqueous solution³⁶. To create microspheres in aqueous medium, phase and extract this solution using an organic solvent that dissolves in water.

8. Quassi emulsion solvent diffusion:

The literature has reported on a unique quasi-emulsion solvent diffusion approach for producing the controlled release microspheres of medicines with acrylic polymers. A quasiemulsion solvent diffusion process may be used to create micro sponges, with an exterior phase made up of polyvinyl alcohol and distilled water^37,38. The medication, ethanol, and polymer make up the interior phase. The polymer concentration is meant to improve plasticity.

The internal phase is introduced to the exterior phase at room temperature after initially being synthesised at 60°C. Following the emulsification process, the mixture is agitated constantly for two hours. After that, the mixture may be filtered to have the micro sponges separated. Next, the goods is cleaned and dried at 40 degrees Celsius in a hoover oven.³⁹ (Fig.10)

Fig. 10: Quassi emulsion solvent diffusion Technique

Characterization of microsphere:

1. Particle size analysis:

The dried microsphere was measured using a calibrated optical micrometre in a microscopic manner. Standard light microscopy (LM) is the most widely utilised approach for micro particular visualisation^40,41.

2. Scanning electron microscopy (SEM) study:

The samples were subjected to scanning electron microscopy (SEM), which was highly qualified for image analysis using a back-scattered electron sensor. Additionally, x-ray diffraction analysis (EDXA) was performed to determine the elemental structure of the samples, identifying specific elements. Using a focused electron beam, the sample was scanned in parallel lines in this approach^42,43.

After that, microspheres were mounted on a sample holder for SEM characterization^45,46. Before that, a sputter coater was used to coat the microspheres with a conductive metal, such as zirconium or platinum. Next, a finely focused electron beam was used to scan the material. The secondary electrons that escaped from the sample's surface were used to determine its surface characteristics⁴⁴.

3. Flow properties:

The flow properties can analyse by determining the carr's compressibility index, Hausner ratio and resting angle of repose. A volumetric cylinder was used to assess bulk density and tapped density⁴⁵.

4. Thermal analysis:

Thermal analysis methods examine these changes on a regular basis by applying prescribed specimen atmospheres and pressures together with planned temperature fluctuations for heating and cooling. Subtle changes in heat and enthalpy, weight gain or loss, Young's modulus, thermal expansion or shrinkage, and gas evolution are among the most often observed characteristics⁴⁶.

5. Determination of percentage yield:

The measured amount of the product, the polymers utilised in the microsphere formulation, and the total number of microspheres generated may all be used to calculate the % yield⁴⁷.

6. Drug content:

To let the particles, settle and then wash, the mixture should be set aside. After transferring 1 mL of the filtrate into a volumetric flask, the volume was adjusted using 0.1 N NaOH. Following the appropriate dilution, the drug was quantified using spectrophotometry^48,49.

7. Determination of drug loading:

The proportion of the weight of the nanoparticles that are connected to the encapsulated product is indicated by the loading ability, which is the quantity of drug loaded per unit of nanoparticle weight. The whole amount of drug captured divided by the entire weight of nanoparticles yields the loading capacity (LC percent). The amount of drug supplied per quantity is represented by the yield, which is a percentage in drug delivery^50,51.

Application of Microsphere:

1. The use of microspheres in vaccine administration:

Safety against microorganisms and their toxic components is a prerequisite for vaccination. The same requirements for efficacy, protection, and cost-effectiveness should all be met by the perfect vaccine. Avoiding serious affects and staying protected are two difficult things to do^52,53. The way of administration has a direct bearing on both the safety factor and the degree of antibody response production. One potential solution to address the shortcomings of intravenous vaccinations is the use of biodegradable delivery technology. Even with those that provide notable advantages, there is still participation in parenteral (subcutaneous, intramuscular, and intradermal) carriers^54,55.

2. Microspheres for the transfer of genes:

Viral vectors, nonanoic liposomes, polycation complexes, and microcapsule technologies are all used in the delivery of genotype drugs. Even though viral vectors are very effective and have a wide range of cell objectives, they are still advantageous for genotype delivery⁵⁶. Nevertheless, when applied in vivo, they cause harmful consequences and immunological reactions. Gene therapy has been considering nonrival delivery techniques as a solution to the limitations of viral vectors. The advantages of a nonrival delivery method include ease of preparation, the ability to target specific cells or tissues, a weakened immune system, unlimited plasmid size, and large-scale, reproducible manufacturing. Polymer will be employed in gene delivery applications as a DNA transporter^57,58.

3. Oral medication administration:

Rabbits have been used to assess the potential of polymer matrix, which typically includes diazepam like an oral drug delivery system. The results indicated that a film with a drug-polymer ratio of 1:0.5 would have been a useful dosage form that is similar to conventional tablet formulations. The ability of the polymer to form films may make it possible to utilise it in the manufacture of film dosage forms in addition to medication tablets^59,60. The sensitivity to pH, in conjunction with both the reactions of the primary amine groups, beginning to create a unique polymer for the administration of drugs orally.

4. Delivery of drugs trans dermally:

Polymer has good properties for creating films. The thickness of the membrane and the crosslinking of a film affect the release profile from the devices. Additionally, chitosan-alginate polyelectrolyte structure has been synthesised in-situ in the form of beads and microspheres for possible use in surgical tools, controlled release systems, and packaging. Impressive and extremely biocompatible polymer gel beads are used in the chemotherapy of inflammatory cytokines for drugs such as prednisolone^61,62. These beads also exhibit prolonged release action, which increases the efficacy of treatment. The properties of the cell wall that was employed were also discovered to affect the amount of drug outflow. The combination of chitosan membrane and chitosan hydrogel, which is known to contain the local anaesthetic lidocaine hydrochloride, is an excellent all-inclusive method for regulated drug release and release dynamics⁶³.

5. Utilising Micro Particulate Carriers for Targeting:

The tried-and-true concept of trying to target is attempting to garner significant attention in the modern day. The drug's own reaction is contingent upon the binding site's accessibility and interaction potential. Generally speaking, it has been shown that pellets may be created by employing extrusion and spherization innovations, such as chitosan and microcrystalline cellulose (MCC)⁶⁴.

6. Individualised Antibodies:

Microspheres that are physiologically immunologic include monoclonal antibodies and targeted microspheres. Utilising to achieve selective targeting to certain organ system areas is one such attempt at targeting. Ultra-specific substances known as monoclonal antibodies attach to a specific area of the body through which absorption takes place^65,66. Two types of adsorptions: non-specific and specific; b. direct; c. coupling through reagent.

7. Intraoral and regional medication administration:

Polymer films were also produced in order to provide therapeutically appropriate intensity solid lipid nanoparticles at the cancer cells. Combining medicine with other substances shows promise for regulated administration across the mouth cavity. For instance, PCL, PLGA, chitosan, and gelatin⁶⁷.

CONCLUSION:

Compared to traditional drug delivery methods, the idea of microsphere drug delivery systems has several advantages, such regulated and sustained distribution. Additionally, drug targeting to several systems, including ocular, intranasal, oral, and IV routes, is made possible by microspheres. Compared to traditional technologies, novel technologies such as immunological microspheres and magnetic microspheres have several benefits and applications. Microspheres are a fantastic affinity for well-known marketing preparations like Protonix, Zilretta, Lumson, Definity, etc., since they increase their efficacy and improve their therapeutic impact.

ACKNOWLEDGEMENT:

Authors are highly thankful to Mata Gujri College of Pharmacy, Kishanganj, Bihar, 855107 India for proving library facility during my literature survey.

CONFLICT OF INTEREST:

There is no conflict of interest.

REFERENCES:

1. Reddy BV, Krishnaveni K. Formulation and evaluation of efavirenz microspheres. Der Pharmacia Letters. 2015; 7(6): 1-9.

2. Sarode SM, Mittal M, Magar RM, Shelke AD, Shrivastava B, Vidyasagar G. Formulation and evaluation of floating microspheres of Glipizide. J Chem Pharm Res. 2011; 3(3): 775-783.

3. Miléna Lengyel, Review Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery, Scientia. Pharmaceutica. 2019; 87- 20.

4. Badilli U, Sen T, Tarimci N. Microparticulate based topical delivery system of Clobetasol Propionate. AAPS PharmSciTech 2011; 12: 949-57.

5. Basarkar G, Shirsath G, Patil S. Development of microspheres containing Diclofenacdiethylamine as sustained release topical formulation. Bull Pharm Res. 2013; 3: 14-22.

6. Labouta H, El-Khordagui L. Polymethacrylate microparticles gel for topical drug delivery. Pharm Res. 2010; 27: 2106-18.

7. S. Y. RAI, et. al., Development and Evaluation of Microsphere based Topical Formulation using Design of Experiments, Indian Journal of Pharmaceutical Sciences. 2016; 78(2): 182-192

8. Tarun Virmani, et. al., Pharmaceutical Application of Microspheres: An Approach for The Treatment of Various Diseases, International Journal of Pharmaceutical Sciences and Research. 2017; 7: 3252-3260.

9. Divya thakur m. pharm, presentation on introduction, advantage, disadvantage, and ideal properties of microsphere, slideshare. Published on Oct 17, 2016.

10. Mukund J. Y, Kantilal B. R, Sudhakar R. N, Floating microspheres: A review, Braz. J. Pharm. 2012; 48(1): 17-30.

11. Kawatra M, Jain U, Ramana J. Recent advances in floating microspheres as gastro-retentive drug delivery system: A review, IJRAPR. 2012; 2(3): 5-23.

12. Singh C, Purohit S, Singh M, Pandey B.L. Design and evaluation of microspheres: A Review. JDDR. 2013; 2(2): 1827.

13. Ramteke K.H, Jadhav V.B, Dhole S.N. Microspheres: As carrieres used for novel drug delivery system. IOSRPHR. 2012; 2(4): 44-48.

14. Dupinder K, Seema S, Gurpreet S, Rana A.C, Biodegradable microspheres: A review. IRJP. 2012; 3(12): 23-27.

15. Saralidze K, Koole L.H, Knetsch M.L.W. Polymeric microspheres for medical applications. Materials. 2010; 3: 37-64.

16. Gogu P.K. Preparation & invivo/ invitro characterisation of Spray Dried Microspheres Formulation Encapsulating 4- Chlorocurcumin. Indian Journal of Pharmaceutical Sciences. 2010; 72: 346-352.

17. Dadhichi K.T. M.Pharm Semester, Formulation and Evaluation of Microspheres, Department of Pharmaceutical Technology Arihant College of Pharmacy Gujarat Technical University.

18. Katarpia S, Middha A, Sandhu P, Ajay B, Bhawana K. Review article on microsphere, Seth G. L. Bihani S.D. College of Technical Education, Institute of Pharmaceutical Sciences and Drug Research. 2011.

19. Singh C, Purohit S, Singh M, Pandey B.L. Design and evaluation of microspheres: A Review, JDDR. 2013; 2(2): 18- 27.

20. Sahil K, Akanksha M, Premjeet S, Bilandi A, Kapoor B. Microsphere: A review. Int. J. Res. Pharm. Chem. 2011; 1(11): 84-98.

21. Pavan K. B, Chandiran I.S, Bhavya B, Sindhuri M. Microparticulate drug delivery system: A Review. Indian Journal of Pharmaceutical Science and Research. 2011; 1(1): 19- 37.

22. Dhakar R.C, Maurya S.D, Sagar B.P.S, Bhagat S, Prajapati S.K, Jain C.P. Variables influencing the drug entrapment efficiency of microspheres: A pharmaceutical review. Der Pharmacia Lettre. 2010; 2(5): 102-116.

23. Parmar H, Bakliwal S, Gujarathi N, Rane B, Pawar S. Different methods of formulation and evaluation of mucoadhesive microsphere. International Journal of Applied Biology and Pharmaceutical Technology. 2010; 1(3): 1157-67.

24. Gogu P.K. Preparation & invivo characterization of spray dried Microspheres formulation Encapsulating 4-chlorocurcumin. Indian Journal of Pharmaceutical Sciences. 2010; 72: 346-352.

25. Li Y P, Machida T Y, Sannan T, Nagai T. Preparation of chitosan microspheres containing fluorouracil using the ‘dryin-oil’ method and its release characteristics. STP Pharm. Sci. 1991; 1: 363–368.

26. Kyotani S, Nishioka Y, Okamura M, Tanaka T, Miyazaki M, Ohnishi S, Yamamoto Y, Ito K, Ogiso T, Tanada S. A study of embolizing materials for chemo-embolization therapy of hepatocellular carcinoma antitumor effect of cis diamminedichloroplatinum (II) albumin microspheres, containing chitin and treated with chitosan on rabbits with VX2 hepatic tumors. Chem. Pharm. Bull. 1990; 40: 2814– 2816.

27. Sinha V.R, Bansal K, Kaushik R, Kumria R, Trehan A. Polycaprolactone microspheres and nanospheres. International Journal of Pharmaceutics. 2004; 278: 1–23.

28. Jameela S R, Jayakrishnan A. Glutaraldehyde crosslinked chitosan microspheres as a long acting biodegradable drug delivery vehicle: studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle. Biomaterials. 1995; 16: 769–775.

29. Hassan E.E, Parish R.C, Gallo J.M. Optimized formulation of magnetic chitosan microspheres containing the anticancer agent oxantrazole. Pharm. Res. 1992; 9: 390– 397

30. Shah S, Qaqish R, Patel V, Amiji M, Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J. Pharm. Pharmacol. 1999; 51: 667–672.

31. Parul T, Varma A L M, Garud N. Preparation and characterization of aceclofenac microspheres, Asianpharmainfo. 2010.

32. Shiraishi S, Imai T, Otagiri M. Controlled release of indomethacin by chitosan–polyelectrolyte complex: optimization and in vivo/in vitro evaluation J. Control Rel. 1993; 25:217–225.

33. Murata Y, Miyamoto E, Kawashima S, Additive effect of chondroitin sulfate and chitosan on drug release from calciuminduced alginate gel beads. J. Control Rel. 1996; 38: 101–108.

34. Rahul N, B Haritha, Reddy C.K, Ashok K, Kumar K.J. Application of chitosan microspheres as drug carriers J.Pharm. Sci. & Res. 2009; 1: 1-12.

35. Lim S T, Martin G P, Berry D J, Brown M B, Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan J Control Rel. 2000; 66: 281–292

36. Berthold A, Cremer K, Kreuter J, Influence of crosslinking on the acid stability and physicochemical properties of chitosan microspheres. STP Pharm. Sci. 1996; 6: 358–364.

37. Alagusundaram M, Madhu S C C, Umashankari K, Attuluri V B, Lavanya C, Ramkanth S, Microspheres as a Novel Drug Delivery System, Chemtech. 2009; 13; 526-534,

38. Bodmeier R, Wang J, Bhagwatwar H J, Microencaps. J Pharm.Sci. 1992; 9: 99–107.

39. Yi M.K, Sun K, Mi R.P, Young J.P, Seung H.B, Hyun W.S. The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres, February 5, (2019), Patent no.10195149.

40. Paul M.W, William D.H, George G W. Glass composites for tissue augmentation, biomedical and cosmetic applications, February 12, (2019), Patent no. 10201633.

41. Franciscus gerardus henricus duijnhoven van, franciscus wilhemus maria gelissen, Microsphere comprising a polymer core, a shell and an absorber, June 30,(2008), Patent no.9050843.

42. Franciscus Wilhelmus Maria Gelissen, Franciscus Gerardus Henricus Van Duijnhoven, The present invention relates to microspheres and to their use, preferably as laser absorbing additive, and to a process for their production, October 16,(2013), Patent No. 9944778.

43. Terry L. Turner, Stuart S. Howards, Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres, May 1, (1989), Patent No. 5017378

44. Cassidy, J.P.; Landcert, N.M.and Quardos, E. Controlled buccal delivery of buprenorphine. J. control. Rel. 1993; 25: 21-29.

45. Dortune, B.; Ozer, L.and Vyanik, N. Development and invitro Evaluation of buccoadhesive pindodlo tablet formulation. Drug Dev. Ind. Pharm. 1998; 24(3): 281-288.

46. Guo, J.H. Bioadhesive polymer buccal patches for buprenorphine-controlled delivery: formulation in vitro adhesive and release properties. Drug Dev.Ind. Pharm. 1994; 20(3): 315- 325.

47. Nagai, T.; Machida, Y.; Suzuki Y.and Ikura, H. Method and preparation for administration to the mucosa and preparation for administration to the mucosa of the oral or nasal cavity. US patent No.4226848, 1980.

48. Chein, Y.W.and Novir, M. Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity. US patent No.5578315, 1996.

49. Fabregas, J.L.and Garcia, N. Invitro studies on buccoadhesive tablet formulations of hydro cortisone hemisuccinate. Drug Dev. Ind. Pharm., 1995; 21(14): 1689-1696.

50. Rathbone, M.J.; Purve, R.: Ghazati, F.A.and HO, P.C. In vivo techniques for studying the oral mucosa absorption characteristics of drugs in animals and humans. In Rathbone, M.J. (ed.), oral mucosal delivery systems, Marcel Dekker Inc.Newyork. 1996; 3(2): 121-156.

51. Lu, M.F.and Hui, H.W. Delivery of rennin inhibitors through mouth mucosa. Drug Dev. Ind. Pharm., 1996; 22(11): 1167-1171.

52. Yukimatsu, K.; Nozaki, Y.; Kakumoto, M.and Ohta, M. Development of a transmucosal controlled release device for systemic delivery of antianginal drugs Dev. Ind. Pharm, 1994; 20(4): 503-534.

53. Hussain, M.A; Aungst, B.J.; Kearney A. and Shefter, E. Buccal and oral bioavailability of naloxone and naltrexone in rats. Int, J. Pharm., 36, 1987,127.

54. Oh, C.K. and Ritschel, W.A. Biopharmaceutical aspects of buccal absorption of insulin rabbits I. Effects of dose, size, Ph & sorption enhancers: in vivo in vitro correlation. Pharm. Res. 1999a; 5(5): 91-100.

55. Oh, C.K. and Ritschel, W.A. Biopharmaceutical aspects of buccal absorption of insulin in rabbits II. Absorption characteristics of insulin through the buccal mucosa. Pharma. Res., 1988b; 5(5): 91- 100.

56. Kellaway, I.W. and warren, S.I. Mucoadhesive hydrogels. Proc. Intern. Symp. Control. Rel. Bioact. Mater. 18, 1991,70-73.

57. Ishida, M.: Nambu, N.and Nagai, T. Highly viscous gel ointment containing carbopol for application to the oral mucosa. Chem Pharm Bull. 1983a; 31: 4561.

58. Ishida, M.; Nambu, N. and Nagai, T. Ointment type oral mucosal dosage form of carbopol containing prednisolone for the treatment of aphtha. Chem. Pharm. Bull. 1983b; 31: 1010.

59. Hoogstrate, A.J., Verhoef, J.C.; Tuk., B.; Pijpers, A.; Vercheijden, J.H.M.; Jungiger, H.E. and Bodde, H.C. Invivo buccal delivery of fluorescein iso thiocyanate– dextran 4400 with glycodeoxy cholate as an absorption enhacer in pigs. J.Pharm.Sci., 1996b; 85(5): 457-460.

60. Burnside, B.A; Keith, A.P. and snipes, W. Micro porous hollow fibers as a peptide delivery system via the buccal activity. proceed inter symp control Rel Bioact mater. 1989; 16: 94.

61. N.K. Jain. Controlled and Novel Drug Delivery, 4 Edition, 236-237, 21.

62. N. Venkateswarlu. Biopharmaceutics and Kinetics. 2004 Edition, 53, 54.

63. Widder K.J., Sanyci A.E., Ovadia H., and Paterson P.Q. Clin. Immuno. Immuno Pathol. 1979; 14: 395.

64. Funden berg H.H., Stites D.P., Caldwel J.L.and Wells J.V. In: Basic and Clinical Immunology, 2 ed., Lange Medical, Los Altosca. 1978

65. Capron A.C., Locht C. and Fracchia G.N (1994) Vaccine.12, 667; Edelman R. vaccine 11, 1361; Drews J. (1984) Immunostimulantien, Klin. Wochenscher. 62, 254; Spier K.E. (1993) Vaccine 11, 1993, 1450.

66. Nachts S. and Martin K. In: The microsponges a novel topical programmable delivery formulation, Marcel Dekker Inc., Newyork. 1990: 299.

67. Kalyan Shweta, Sharma Parmod Kumar et al. Recent Advancement in Chitosan Best Formulation And Its Pharmaceutical Application. Pelagia Research Library. 2010; 1(3): 195-210.

Received on 07.06.2024 Revised on 14.08.2024

Accepted on 20.10.2024 Published on 18.12.2024

Available online on December 21, 2024

Asian J. Pharm. Tech. 2024; 14(4):399-406.

DOI: 10.52711/2231-5713.2024.00063

Category	Drug	Use	Method	Result
NSAID	Acelofenac²⁵	anti-inflammatory	By dissolving drug in polymer	Controlled release and minimize local side effect
Antibiotic	Amoxicillin²⁶ Gentamicin²⁷	for helicobacter pylori infection eliminating infection	Crosslinking double emulsion technique	Slow-release rate Controlled release
Anti-inflammatory	Indomethacin²⁸ Diclofennac²⁹ Ketoprofen³⁰	Anti-inflammatory	Co-matrix method Coacervation phase separation Multiple emulsion o/w/o	Decrease in release rate Suppress the release rate Modulate drug release
Cardiac agent	Nifedipine^31,32 Propanolol^31,32 Dilitazam³³	Calcium channel blockers ……. Calcium channel blockers	Encapsulation Emulsification coacervation technique Controlled coacervation technique	More drug entrapment efficiency Enhance drug encapsulation efficiency Retard drug release
Steroidal	Progesterone³⁴	Steroid	Crosslinking	Maintain plasma drug concentration
Antidiabatic agent	Insulin³⁵	Antihyperglycemic	…..	Improve systemic absorption
Diuretics	Furosemide³⁶	Diuretic	Crosslinking	Reduce effect of external variables
Anticancer	Fluoroucil³⁷ Cisplatin³⁸ Mitoxantrone Oxantrazol	For targeted delivery to treat cerebral tumors Antitumors activity Antitumor anticancer	Dry-in-oil w/o emulsion system crosslinking technique combined emulsion	Slowdown of release rate of drug Reduce release rate Minimize drug toxicity and minimize therapeutic efficacy Enhance the delivery of drug in brain 100 times